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Introduction
Coronary artery calcification (CAC) has been strongly 
established as an independent predictor of adverse events, 
with a significant incremental prognostic value over 
traditional risk stratification algorithms (1-3). Asymptomatic 
and even symptomatic patients with absence of calcifications 
(CAC zero) assessed by cardiac computed tomography have 
a very low incidence of events at long-term follow-up (1). 
Furthermore, CAC progression has been associated with 
higher rates of events (4). 
Routine medical therapy for coronary artery disease 
(CAD) aims to slow the progression of atherosclerosis. 
Indeed, a vast number of randomized studies and meta-
analysis have shown the effectiveness of statins in secondary 
prevention, not only by providing a significant reduction in 
coronary events, but also in their ability to slow progression 
and even promote plaque regression (5-7). However, 
evidence regarding the effect of routine medical therapy 
on CAC has yielded conflicting results, with initial studies 
showing significant CAC regression, and contemporaneous 
data showing rather the opposite (8-12). Furthermore, 
complementary prescription of comprehensive lifestyle 
modification on top of contemporary secondary prevention 
strategies in patients with CAD has no impact on CAC 
progression but significant benefit for blood pressure, heart 
rate and the need of anti-ischemic medication (13). 
Accordingly, there is currently a great controversy on 
whether progression of CAC is a sign of progression or 
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stabilization of CAD. 
CAC scoring by computed tomography: Etiology 
and prognostic value
CAC is a hallmark of atherosclerosis, and is highly related 
to increasing age (14). Since life expectancy has significantly 
improved in the past decades, it is of utmost importance 
to refine the role of calcium as a prognostic marker. Both 
ex vivo and intravascular ultrasound (IVUS) studies have 
shown that CAC is closely related to atherosclerotic plaque 
burden, although the molecular basis of this process remains 
uncertain (15-17). Recent molecular imaging studies support 
the current notion that vascular calcification is not a passive 
degenerative process, but actually an active process that 
leads to ectopic mineralization promoted by the expression 
of multiple pro-osteogenic cytokines, transcription factors, 
and mineralization-regulating proteins by macrophages and 
other inflammatory cells (18). In this regard, fluorescence 
molecular multimodality imaging has shown potential to 
provide insightful data concerning arterial osteogenesis at 
much earlier stages of atherosclerosis (19,20).
In one of the first studies addressing the association 
between CAC and plaque burden in post mortem specimens, 
Sangiorgi et al. showed a significant correlation between 
calcium and plaque areas, being this significant both on a 
per heart and a per vessel basis (17). Nonetheless, the extent 
of CAC is not strongly related to the degree of luminal 
stenosis on a per lesion basis (17,21). Indeed, despite CAC is 
commonly associated to advanced stages of atherosclerosis 
and to a more stable and quiescent phenotype, calcifications 
can be present in early stages of CAD, as discussed above. 
Besides, most thin-cap fibroatheroma lesions, the main 
substrate of plaque rupture, show microcalcifications within 
the necrotic core or at the periphery (14). In addition, 
studies using advanced imaging including micro-CT 
and optical coherence tomography (OCT) have related 
microcalcifications within the thin fibrous cap to vulnerable 
features, and to an increased risk of plaque disruption (22,23). 
Before the widespread installation of multidetector 
computed tomography (MDCT), early studies using 
electron beam CT established CAC as an independent 
predictor of events with an incremental prognostic value 
over traditional risk stratification algorithms (2,24). 
CAC assessment by MDCT is a simple procedure that 
does not require contrast administration or heart rate 
lowering medication. CAC has high sensitivity and negative 
predictive value for the detection of obstructive CAD. 
Indeed, not only the absence of coronary calcifications (CAC 
zero) has shown a nearly 100% sensitivity and negative 
predictive value to rule out obstructive CAD, as discussed 
above, but also a CAC >400 has shown modest specificity 
and positive predictive value to identify obstructive 
CAD (1,25,26). A number of studies have explored the 
relationship between CAC scoring and myocardial perfusion 
imaging (MPI). Among them, one study including low risk 
patients showed that only 2% of patients with CAC <100 
have abnormal MPI studies, compared to 31% of patients 
with CAC >400 (27,28). A CAC score ≥709 has been 
suggested as the optimal cutoff for detecting CAD missed 
by SPECT imaging, improving the sensitivity of SPECT 
from 76% to 86% (29).
Furthermore, CAC scoring is associated to a very 
low effective radiation dose (~1.0 mSv) and it has been 
extensively validated as an independent predictor of major 
adverse cardiac events and total mortality in asymptomatic 
patients, providing a significant incremental value over 
traditional risk factors and functional studies (30-33). 
Overall, the robust evidence available has led to the inclusion 
of CAC in a number of guidelines for risk stratification of 
asymptomatic intermediate risk patients (34,35).
A number of absolute CAC score thresholds have been 
defined for risk prediction ranging from very low risk to very 
high risk of events (CAC 0; 1–99; 100–399; 400–999; and 
≥1,000), being asymptomatic individuals with CAC >400 at 
a similar risk of events than patients with established CAD 
(31-33). Nevertheless, the close relationship between CAC 
and age mandates an assessment according to age and sex 
(Figure 1). In fact, Becker et al. have shown that CAC above 
the 75th percentile is associated with significantly higher 
rates of cardiovascular death and myocardial infarction than 
patients with CAC scores below the 75th percentile (36).
Asymptomatic and even symptomatic patients with 
absence of calcifications (CAC zero) assessed by MDCT 
have a very low incidence of events at long-term follow-
up (3,17). Of note, a large body of evidence renders the 
absence of calcification a 5-year safety window, with a 0.10% 
annual risk of events (2,32,37-41).
Notwithstanding, the absence of calcium does not rule out 
the presence of plaque. Indeed, CAC zero in symptomatic 
patients should lead to a cautious interpretation due to a 
number of factors. Firstly, approximately 30% of acute 
coronary thromboses, particularly in young women and in 
smokers, are attributed to plaque erosion, a type of plaque 
that has no lipid core or calcifications and is therefore so far 
undetectable to any invasive and non-invasive technique, 
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although recent studies suggested that they might be 
detected by OCT (42,43). Secondly, spotty calcifications 
might be occasionally undetected by the 3 mm slices that 
are routinely used for CAC assessment by MDCT. Spotty 
calcifications can be more easily identified using either 
catheter-based techniques (IVUS and OCT) or non-invasive 
imaging using MDCT coronary angiography. This feature 
(defined by IVUS as lesions 1 to 4 mm in length containing 
an arc of calcification of <90°, and <3 mm by MDCT) is 
commonly observed in culprit lesions of patients with acute 
coronary syndromes, although it has a low positive predictive 
value for the prediction of events compared to other high 
risk findings such as positive remodeling or low attenuation 
plaques (44,45). Besides, the size of the aforementioned 
microcalcifications within the thin fibrous cap (<65 μm) 
precludes non-invasive detection by means of MDCT and 
even by IVUS.
Other worth mentioning lesions are calcified nodules. These 
protrusive superficial lesions, although very infrequent, have 
been related to plaque rupture and acute coronary thrombosis, 
and MDCT might be able to identify them (43,46).  
Meaning of CAC progression
Progression of CAD is undoubtedly related to adverse 
clinical outcomes. Based on the robust evidence confirming 
the role of CAC as an independent predictor of death and 
myocardial infarction, and the fact that CAC is closely 
associated to the extent of CAD; it might be assumed that 
CAC progression would also portent a worse prognosis 
(32,47,48). 
This might potentially be related to the fact that spotty 
calcifications are associated with a larger atherosclerotic 
burden and to accelerated plaque progression despite use of 
secondary prevention strategies (49).
Nonetheless, evidence in this regard is inconclusive and 
the clinical significance of CAC progression remains to be 
established. In a consecutive series of 4,609 asymptomatic 
individuals who underwent serial scanning, Budoff et al. 
found that CAC progression (defined as difference between 
square root of baseline and square root of follow-up CAC 
score >2.5; or >15% yearly increase) added a significant 
incremental value over baseline CAC, time between scans, 
and demographical characteristics in predicting all-cause 
mortality (4). 
More recently, a subanalysis of the Multi-Ethnic Study of 
Atherosclerosis (MESA) study showed a linear relationship 
between CAC progression and risk of cardiovascular 
events, and identified a three- to six-fold increased rate of 
events in those with an annual progression ≥300 units (50). 
Figure 1 Hypothetical case-scenario of a 55-year-old asymptomatic male with hypercholesterolemia. At baseline, he had a CAC score of 120 
(82th percentile). After three years, the patient remained asymptomatic, with normal lipid profile since lipid-lowering therapy with statins was 
implemented. At follow-up, a significant progression of CAC was observed (CAC 190, annual increase 19%). Paradoxically, the same CAC 
at follow-up can both be related to a significant plaque progression, or to plaque mineralization as an expression of stabilization. Likewise, 
although CAC at any time point is a robust independent predictor of events, it can reflect conflicting interpretations (i.e., in two patients 
with the same CAC and CAC percentile; one can indicate extensive plaque burden with multiple spotty and focal calcifications, and the 
other can represent stable fibrocalcific plaques). This example represents the limitations of CAC for longitudinal assessments, particularly if 
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CAC progression has been related to several traditional 
modifiable and non-modifiable cardiovascular risk factors, 
as well as to novel risk factors such as C-reactive protein, 
cystatin-C, and to low adiponectin levels (51-54). However, 
there are no conclusive findings regarding their specific 
predictive value.
Routine medical therapy for CAD aims to slow the 
progression of atherosclerosis. Conventional and novel, 
predominantly lipid lowering, pharmacological strategies 
have attempted to achieve plaque stabilization and even 
shown to promote plaque regression (7,55,56). More in 
particular, aggressive lipid-lowering with high-dose statins 
has overall accomplished this goal, as assessed by several 
IVUS studies (6,7,57). 
Nonetheless, the significance of CAC alterations with 
regard to the underlying shift in plaque volume remains 
unknown. CAC progression might be attributed to 
plaque progression into a more unstable phenotype with 
accumulation of microcalcifications, and this would be 
justified by the aforementioned evidence supporting the 
deleterious role of CAC progression. However, CAC 
progression in the context of lifestyle modification and lipid 
lowering therapies might also be related to a shift towards a 
more stable phenotype. This paradox is portrayed in Figure 1. 
In other words: (I) does CAC progression mean plaque 
progression or plaque stabilization? 
Effect of statins on CAC
Lipid lowering therapies showed a strikingly improved 
clinical outcome of patients with CAD, both in the primary 
and secondary prevention realms (58,59). Reversal of 
coronary atherosclerosis with intensive statin therapy 
has been reported in both the peripheral and coronary 
circulation using diverse invasive and non-invasive imaging 
tools (6,7,60-64). Indeed, a recent study using IVUS 
radiofrequency data (RF) analysis demonstrated that in 
patients with ST-elevation acute myocardial infarction 
(STEMI) undergoing primary percutaneous coronary 
intervention, high-dose rosuvastatin therapy over 13 
months leads to regression of coronary atherosclerosis in 
non culprit vessels. In this study, 74% of patients showed 
regression in at least one non-culprit vessel. Of note, 
plaque regression could not be attributed to changes in the 
necrotic core extent or in the number of IVUS-derived 
thin cap fibroatheromas (65). 
Similarly, the long term results of the Study of coronary 
Atheroma by inTravascular Ultrasound: the effect of 
Rosuvastatin vs. atorvastatiN (SATURN) demonstrated that 
high-dose statin therapy promoted a significant regression 
in percent atheroma volume, despite both the necrotic core 
volume and the frequency of fibroatheromas remained 
stable. Of note, a significant increase in dense calcium 
volume was reported in this study (57).
Accordingly, the mechanisms involved in plaque stabilization 
and regression are still not fully understood, being so far 
ascribed to changes in LDL-C and HDL-C (60,64,66).
The observed plaque stabilization effect induced by 
statins might potentially be attributed to pleomorphic 
effect including a decrease in the lipid content of plaques, a 
reduction in the inflammatory burden and an improvement 
in endothelial function; all promoting a more stable 
phenotype (67-71). Notwithstanding, most evidence in this 
regard remains inconclusive or speculative. 
CAC was conceived as a non-invasive imaging tool 
aimed at non-invasive assessment of CAD (72). Later on, it 
has been proposed as a useful tool to monitor the impact of 
diverse medical therapies on atherosclerosis (8).
Evidence regarding the effect of routine medical therapy 
on CAC has yielded conflicting results, with initial studies 
showing significant CAC regression, and contemporaneous 
data showing rather the opposite (8-10,73).
Indeed, a study published in the New England of Medicine 
in 1998 reported a significant reduction in coronary 
artery calcium volume assessed using electron-beam CT, 
proposing a new surrogate endpoint for future prospective 
clinical studies exploring the effect of drug therapies on 
CAD (8). The study of Callister et al. promoted the idea 
that CAC regression could be used as an appealing imaging 
endpoint of both primary and secondary prevention 
strategies (74-76).
Nonetheless, all the randomized controlled clinical trials 
performed have consistently reported a persistent CAC 
progression despite intensive lipid-lowering treatment 
(Table 1) (10,77-80). In fact, a recent meta-analysis that 
included 8 pooled clinical trials evaluating the effect of high 
intensity, low intensity or no statin on the percent atheroma 
volume as assessed by IVUS, showed that aggressive statin 
therapy induced a significant reduction in percent atheroma 
volume. Of note, high intensity treatment with statins also 
promoted a significant increase in calcium index compared 
to the other two groups (11). Indeed, a recent meta-analysis 
showed continuing progression of coronary calcification 
despite treatment with statins (12).
Therefore, in brief: (I) CAC progression is an independent 
predictor of events; (II) statins promote plaque regression; 
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and (III) statins promote CAC progression. 
These paradoxical results are puzzling and warrant the 
conduction of further studies aimed at the pathophysiological 
and clinical discrimination between plaque volume 
progression and CAC progression. 
One of the potential explanations might be that 
conventional reading of CAC studies does not make a 
distinction between spotty calcifications and dense calcium. 
Future discrimination between these two completely 
different sources of coronary calcium might become a major 
breakthrough in CAC imaging, since spotty calcifications 
have been recognized as a marker of high risk plaques (81,82). 
Regarding future alternative therapeutic approaches, the 
combined application of molecular imaging agents with 
anticalcification drugs such as bisphosphonate might potentially 
enable targeting at different stages of the disease (18). 
Future perspectives
Should the Agatston score be revisited? CAC progression 
seems inevitable and predictable, with limited influence of 
cardiovascular risk factors (83). 
The unquestioned clinical benefit of statins observed in 
secondary prevention surpasses the expected benefit based 
on their lipid lowering effect, being this at least in part 
explained by their supposed ability to decrease the lipid 
and macrophage content and to increase the fibrous cap 
thickness in atherosclerotic plaques, promoting a shift into 
more stable, calcified lesions (69,84,85). 
As it was recently postulated by Shaw et al., CAC 
predicts risk via an intrinsic property or by being a marker 
of coexisting high-risk plaques in a stabilization process 
commanded by coronary artery mineralization (86)? 
Accordingly, based on the available conflicting evidence, 
it remains unknown whether CAC progression as a single 
endpoint can discriminate between two opposite outcomes 
such as plaque stabilization and atherosclerotic plaque 
progression (Figure 1). As discussed above, conventional 
CAC scoring comprises the quantification of coronary 
calcifications both on per vessel and per patient basis, 
leading to robust risk stratification of asymptomatic patients 
as a once-only study. Future developments of the technique 
warrant the conception of second-generation CAC capable 
to discriminate between different calcification patterns and 
spatial distribution, possibly leading to a refinement of the 
prognostic value and to the application of the technique to 
longitudinal studies (46).
Until then, the usefulness of CAC once the patient is 
under statin treatment should be limited. Indeed, a number 
of medical therapies and even supplementations often 
used for the management of patients with hypertension or 
related complications such as atrial fibrillation have shown 
a significant association to CAC and/or plaque stabilization 
(55,87,88). The finding of inexorable CAC progression 
despite the implementation of intensive contemporaneous 
medical therapy might suggest that further understanding 
of this phenomenon should be undertaken before the 
implementation of CAC as a surrogate endpoint for 
longitudinal studies, or for prospective follow-up of patients 
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Table 1 Randomized controlled trials exploring the effect of statins on CAC
Study or author Reference n Treatment arm Follow-up
Percent CAC change (%/year) 
Treatment Control
SALTIRE (10) 102 Atorvastatin 24 months 26 18
Terry et al. (77) 80 Simvastatin 12 months 9 5
Schmermund et al. (78) 366 High dose atorvastatin 12 months 27 25
BELLES (79) 475 High dose atorvastatin 12 months 15 14
St. Francis Heart Study (80) 1,005 Atorvastatin 52 months 38 36
CAC, coronary artery calcium; SALTIRE, Scottish Aortic Stenosis and Lipid Lowering Therapy, Impact on Regression; BELLES, 
Beyond Endorsed Lipid Lowering with EBT Scanning.
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